ATE325122T1 - Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung - Google Patents

Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Info

Publication number: ATE325122T1
Authority: AT; Austria
Prior art keywords: production; therapeutic use; piperazinylacylpiperidine; derivatives; piperazinylacylpiperidine derivatives
Prior art date: 2002-06-07

Application number

AT03757109T

Other languages

English (en)

Inventor

Francoise Bono

Michael Bosch

Santos Victor Dos

Jean Marc Herbert

Dino Nisato

Bernard Tonnerre

Jean Wagnon

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-05

Publication date

2006-06-15

2003-06-05 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE325122T1 publication Critical patent/ATE325122T1/de

Links

230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT03757109T 2002-06-07 2003-06-05 Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung ATE325122T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0207001		2002-06-07

Publications (1)

Publication Number	Publication Date
ATE325122T1 true ATE325122T1 (de)	2006-06-15

Family

ID=29724874

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03757109T ATE325122T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
AT03757108T ATE336491T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT03757108T ATE336491T1 (de)	2002-06-07	2003-06-05	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung

Country Status (29)

Country	Link
US (2)	US7294628B2 (de)
EP (2)	EP1513836B1 (de)
JP (2)	JP4441401B2 (de)
KR (1)	KR100970812B1 (de)
CN (1)	CN100448875C (de)
AR (2)	AR040247A1 (de)
AT (2)	ATE325122T1 (de)
AU (2)	AU2003255645A1 (de)
BR (1)	BR0311828A (de)
CA (1)	CA2487840C (de)
CY (2)	CY1107330T1 (de)
DE (2)	DE60307632T2 (de)
DK (2)	DK1513836T3 (de)
EA (1)	EA007501B1 (de)
ES (2)	ES2264001T3 (de)
HR (1)	HRP20041157B1 (de)
IS (1)	IS2302B (de)
MA (1)	MA27233A1 (de)
ME (1)	MEP11508A (de)
MX (1)	MXPA04012341A (de)
NO (1)	NO329669B1 (de)
NZ (1)	NZ537044A (de)
PL (1)	PL208711B1 (de)
PT (2)	PT1513835E (de)
RS (2)	RS52588B (de)
TW (2)	TWI319400B (de)
UA (1)	UA77526C2 (de)
WO (2)	WO2003104226A1 (de)
ZA (1)	ZA200409823B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2862968B1 (fr) *	2003-12-01	2006-08-04	Sanofi Synthelabo	Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) *	2003-12-01	2006-08-04	Sanofi Synthelabo	Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
EP1706392A2 (de) *	2004-01-08	2006-10-04	Syngenta Participations AG	Pestizide heterocyclische dihalogenallylverbindungen
WO2006008259A1 (en) *	2004-07-16	2006-01-26	Janssen Pharmaceutica N.V.	Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders
EP2289510A1 (de) *	2004-09-20	2011-03-02	Xenon Pharmaceuticals Inc.	Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten
WO2006113097A2 (en)	2005-04-15	2006-10-26	The University Of North Carolina At Chapel Hill	Methods of facilitating cell survival using neurotrophin mimetics
JP5147866B2 (ja) *	2007-03-15	2013-02-20	メルク・シャープ・アンド・ドーム・コーポレーション	グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
RU2497819C2 (ru) *	2007-05-21	2013-11-10	Ривайва Фармасьютикалс, Инк.	Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
FR2932482B1 (fr) *	2008-06-13	2010-10-08	Sanofi Aventis	Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) *	2008-06-13	2010-10-08	Sanofi Aventis	Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
WO2011060262A1 (en)	2009-11-12	2011-05-19	Pharmatrophix, Inc.	Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en)	2009-11-12	2019-04-30	Pharmatrophix, Inc.	Crystalline forms of neurotrophin mimetic compounds and their salts
AU2010333338A1 (en)	2009-12-14	2012-08-02	Merck Patent Gmbh	Sphingosine kinase inhibitors
FR2953839A1 (fr) *	2009-12-14	2011-06-17	Sanofi Aventis	Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr)	2009-12-14	2012-03-16	Sanofi Aventis	Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (de)	2011-12-20	2013-06-26	Sanofi	Neuartige therapeutische Verwendung von p75-Rezeptorantagonisten
US12435078B2 (en)	2017-09-18	2025-10-07	Gfb (Abc), Llc	Pyridazinones and methods of use thereof
LT3852533T (lt)	2018-09-18	2024-06-10	Gfb (Abc), Llc	Piridazinonai ir jų naudojimo būdai
CA3136632A1 (en)	2019-04-11	2020-10-15	Goldfinch Bio, Inc.	Spray-dried formulation of a pyridazinone trpc5 inhibitor
EP3858439A1 (de) *	2020-02-03	2021-08-04	Esteve Pharmaceuticals, S.A.	Amidderivate mit multimodaler aktivität gegen schmerzen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4994455A (en) *	1987-10-26	1991-02-19	Pfizer Inc.	Anti-anxiety agents
FR2747041B1 (fr) *	1996-04-05	1998-05-22	Cird Galderma	Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en)	1999-05-17	2002-10-22	Queen's University At Kingston	Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr)	2000-01-06	2002-02-15	Sanofi Synthelabo	Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

2003
- 2003-05-06 UA UA20041210010A patent/UA77526C2/uk unknown
- 2003-06-05 DE DE60307632T patent/DE60307632T2/de not_active Expired - Lifetime
- 2003-06-05 BR BR0311828-2A patent/BR0311828A/pt not_active IP Right Cessation
- 2003-06-05 NZ NZ537044A patent/NZ537044A/en not_active IP Right Cessation
- 2003-06-05 ME MEP-115/08A patent/MEP11508A/xx unknown
- 2003-06-05 ES ES03757109T patent/ES2264001T3/es not_active Expired - Lifetime
- 2003-06-05 DK DK03757109T patent/DK1513836T3/da active
- 2003-06-05 JP JP2004511296A patent/JP4441401B2/ja not_active Expired - Fee Related
- 2003-06-05 KR KR1020047019860A patent/KR100970812B1/ko not_active Expired - Fee Related
- 2003-06-05 ES ES03757108T patent/ES2271637T3/es not_active Expired - Lifetime
- 2003-06-05 MX MXPA04012341A patent/MXPA04012341A/es active IP Right Grant
- 2003-06-05 AU AU2003255645A patent/AU2003255645A1/en not_active Abandoned
- 2003-06-05 CA CA2487840A patent/CA2487840C/en not_active Expired - Fee Related
- 2003-06-05 EA EA200401470A patent/EA007501B1/ru not_active IP Right Cessation
- 2003-06-05 HR HR20041157 patent/HRP20041157B1/xx not_active IP Right Cessation
- 2003-06-05 PT PT03757108T patent/PT1513835E/pt unknown
- 2003-06-05 AU AU2003255644A patent/AU2003255644B2/en not_active Ceased
- 2003-06-05 CN CNB038188082A patent/CN100448875C/zh not_active Expired - Fee Related
- 2003-06-05 WO PCT/FR2003/001686 patent/WO2003104226A1/fr not_active Ceased
- 2003-06-05 DK DK03757108T patent/DK1513835T3/da active
- 2003-06-05 PT PT03757109T patent/PT1513836E/pt unknown
- 2003-06-05 US US10/516,808 patent/US7294628B2/en not_active Expired - Lifetime
- 2003-06-05 PL PL374729A patent/PL208711B1/pl not_active IP Right Cessation
- 2003-06-05 JP JP2004511295A patent/JP4437075B2/ja not_active Expired - Fee Related
- 2003-06-05 US US10/516,704 patent/US7468368B2/en not_active Expired - Lifetime
- 2003-06-05 AT AT03757109T patent/ATE325122T1/de active
- 2003-06-05 WO PCT/FR2003/001685 patent/WO2003104225A1/fr not_active Ceased
- 2003-06-05 RS RS20050014A patent/RS52588B/sr unknown
- 2003-06-05 EP EP03757109A patent/EP1513836B1/de not_active Expired - Lifetime
- 2003-06-05 DE DE60305037T patent/DE60305037T2/de not_active Expired - Lifetime
- 2003-06-05 RS YUP-2005/0014A patent/RS20050014A/sr unknown
- 2003-06-05 EP EP03757108A patent/EP1513835B1/de not_active Expired - Lifetime
- 2003-06-05 AT AT03757108T patent/ATE336491T1/de active
- 2003-06-06 TW TW092115443A patent/TWI319400B/zh not_active IP Right Cessation
- 2003-06-06 AR ARP030102018A patent/AR040247A1/es active IP Right Grant
- 2003-06-06 TW TW092115416A patent/TWI283671B/zh not_active IP Right Cessation
- 2003-06-06 AR ARP030102017A patent/AR040246A1/es active IP Right Grant
2004
- 2004-12-02 IS IS7579A patent/IS2302B/is unknown
- 2004-12-03 ZA ZA200409823A patent/ZA200409823B/en unknown
- 2004-12-03 MA MA27980A patent/MA27233A1/fr unknown
- 2004-12-06 NO NO20045331A patent/NO329669B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101094T patent/CY1107330T1/el unknown
- 2006-11-15 CY CY20061101660T patent/CY1105784T1/el unknown

Also Published As

Publication number	Publication date
TW200400185A (en)	2004-01-01
RS52588B (sr)	2013-04-30
PL208711B1 (pl)	2011-05-31
EA200401470A1 (ru)	2005-06-30
CA2487840C (en)	2011-05-17
HRP20041157A2 (en)	2005-06-30
AU2003255644B2 (en)	2009-02-05
CY1107330T1 (el)	2012-11-21
RS20050014A (sr)	2007-06-04
KR20050008802A (ko)	2005-01-21
UA77526C2 (en)	2006-12-15
ATE336491T1 (de)	2006-09-15
DK1513835T3 (da)	2006-12-27
WO2003104226A1 (fr)	2003-12-18
MEP11508A (en)	2010-06-10
US20050176722A1 (en)	2005-08-11
CN1675203A (zh)	2005-09-28
HRP20041157B1 (en)	2012-11-30
US7294628B2 (en)	2007-11-13
AR040247A1 (es)	2005-03-23
CY1105784T1 (el)	2011-02-02
EP1513836A1 (de)	2005-03-16
PL374729A1 (en)	2005-10-31
DK1513836T3 (da)	2006-09-11
ZA200409823B (en)	2006-07-26
EA007501B1 (ru)	2006-10-27
JP2005533051A (ja)	2005-11-04
AU2003255644A1 (en)	2003-12-22
AR040246A1 (es)	2005-03-23
JP2005534661A (ja)	2005-11-17
DE60307632D1 (de)	2006-09-28
DE60305037T2 (de)	2006-12-14
PT1513835E (pt)	2006-12-29
BR0311828A (pt)	2005-03-29
US20060167007A1 (en)	2006-07-27
NO329669B1 (no)	2010-11-29
ES2264001T3 (es)	2006-12-16
EP1513835B1 (de)	2006-08-16
TWI319400B (en)	2010-01-11
TWI283671B (en)	2007-07-11
EP1513835A1 (de)	2005-03-16
TW200407321A (en)	2004-05-16
EP1513836B1 (de)	2006-05-03
DE60305037D1 (de)	2006-06-08
WO2003104225A1 (fr)	2003-12-18
US7468368B2 (en)	2008-12-23
HK1076110A1 (zh)	2006-01-06
NO20045331L (no)	2005-03-07
PT1513836E (pt)	2006-09-29
IS2302B (is)	2007-10-15
CN100448875C (zh)	2009-01-07
KR100970812B1 (ko)	2010-07-16
IS7579A (is)	2004-12-02
JP4437075B2 (ja)	2010-03-24
DE60307632T2 (de)	2007-08-09
AU2003255645A1 (en)	2003-12-22
MXPA04012341A (es)	2005-09-30
CA2487840A1 (en)	2003-12-18
MA27233A1 (fr)	2005-02-01
NZ537044A (en)	2006-08-31
JP4441401B2 (ja)	2010-03-31
ES2271637T3 (es)	2007-04-16

Legal Events

Date

Code

Title

Description

2007-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1513836

Country of ref document: EP

Publication	Publication Date	Title
ATE441635T1 (de)	2009-09-15	4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
ATE336491T1 (de)	2006-09-15	Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE294171T1 (de)	2005-05-15	Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE310003T1 (de)	2005-12-15	Benzodiazepin-derivate, deren herstellung und anwendung
ATE372998T1 (de)	2007-09-15	1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE409184T1 (de)	2008-10-15	Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE395342T1 (de)	2008-05-15	2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE412635T1 (de)	2008-11-15	Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
DE60336907D1 (de)	2011-06-09	Spirobifluorenderivate, deren herstellung und deren verwendung
DE50312295D1 (de)	2010-02-11	8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE469131T1 (de)	2010-06-15	Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DE60107859D1 (de)	2005-01-20	Benzimidazolderivate, ihre herstellung und therapeutische verwendung
ATE319684T1 (de)	2006-03-15	Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE316966T1 (de)	2006-02-15	Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE60235547D1 (de)	2010-04-15	En daraus, deren herstellung und verwendung
ATE312828T1 (de)	2005-12-15	Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE60334632D1 (de)	2010-12-02	Mechanolumineszenzstoff und dessen herstellung
IS7829A (is)	2005-04-28	Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
DE60321372D1 (de)	2008-07-10	3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE542806T1 (de)	2012-02-15	Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE423119T1 (de)	2009-03-15	Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE69905714D1 (de)	2003-04-10	Platinkomplex, dessen herstellung und dessen therapeutische anwendung
ATE417846T1 (de)	2009-01-15	Aminotropanderivate, deren herstellung und deren therapeutische verwendung
ATE474840T1 (de)	2010-08-15	6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE60304596D1 (de)	2006-05-24	In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung